Faron Pharmaceuticals Ltd (LON:FARN) has filed two patents to protect a drug it is developing that uses the body’s own immune system to kill cancer.
As the name suggests Faron’s treatment Clevegen does something new and clever.
Binding to the Clever-1 cell surface receptor, it converts the environment around a tumour from being suppressive to immune stimulating.
The filings have been made in Finland but should be rolled out globally under the Patent Co-operation Treaty.
Chief executive Markku Jalkanen said: "We are very excited about these new filings.
“The new patents, if granted, will provide a significant extension to our strong intellectual property coverage on Clever-1 and presents new opportunities for Clevegen, which also has the potential to be used in combination therapies with other immune checkpoint compounds.
“We believe that Clevegen also has the potential for use in chronic infections as well as vaccination protocols, both of which are dependent on immune balance between activation and suppression."